The One Number That Could Rewrite the Story for CoreWeave Stock

The market is focused on today’s costs, but the company has already sold a future that looks entirely different.

If you’ve held CoreWeave (CRWV) stock over the past year, you don’t need me to tell you it’s been a tough ride. The stock currently trades about 48% below its 52-week high, a frustrating position for a company at the center of the AI buildout. But buried in the latest earnings call is a figure so large it almost forces you to reconsider the entire narrative.

That figure isn’t revenue or earnings. It’s the backlog.

A Backlog Approaching $100 Billion

In the first quarter alone, CoreWeave signed more than $40 billion of new commitments, swelling its contracted revenue backlog to nearly $100 billion. Let’s put that in perspective. The company’s revenue over the last twelve months was $6.23 billion. This surge represents a step-change in scale that goes beyond simple growth, all of it pre-sold and locked in. The backlog grew from $66.8 billion just one quarter prior, showing that demand is both strong and accelerating. This demand is also diversifying, with management noting they now have 10 customers committed to spending at least $1 billion each, including new or expanded deals with firms like Anthropic, Meta, and Jane Street.

Why Isn’t The Stock Flying?

Because a backlog is a promise, not a profit. And right now, the costs of fulfilling that promise are hitting the income statement hard. The company’s adjusted operating margin in Q1 was just 1%, which management called its expected “low point.” The spending required to build out this capacity is immense, with full-year CapEx now guided between $31 billion and $35 billion, partly due to increases in component pricing. This is the question nagging investors: can CoreWeave actually execute this large build-out profitably, especially with a steep climb back to double-digit margins promised by year-end?

A ‘Structural Shift’ In The Business Model

Here’s where the bull case finds its footing. Management argues the margin squeeze is a temporary, timing-based issue. As large-scale new data centers come online, costs are recognized before revenue, creating a short-term drag. More importantly, the company says it is largely “insulated from the price inflation on some of the components because we include that in our pricing.” Instead of absorbing the higher costs, they’re passing them on in these multi-year deals. And crucially, they’re funding this expansion with cheaper money. A recent financing deal was priced at a cost of “less than 6%,” a rate management calls a “structural shift” that lowers the hurdle for profitable growth.

The market seems caught up in the near-term execution challenges. But the real story might be the sheer, locked-in scale of what’s coming. The debate isn’t about whether the demand exists, it’s been contracted. The opportunity is in the market eventually pricing in a future that CoreWeave has already sold.

How Do You Spot This Before The Crowd Does?

An opportunity like this only counts once it starts showing up in the numbers, and the first hard place it surfaces is management’s guidance. The moment a company can actually see the new revenue coming, it raises its forecast, and a raised forecast that the market is already rewarding is about the cleanest proof a story like this is turning real. Edwards Lifesciences (EW), F5 (FFIV), and Flex (FLEX) are flashing exactly that signal right now. Our Guidance Momentum screen tracks every S&P 500 name where a rising forecast is already meeting real price momentum, so you can hunt for the next opportunity like this one while it is still early. And if you would rather own the whole theme than bet on this one name, our ETF Scorecard shows how the large-cap technology funds compare.

Do Not Let One Winner Become Your Only Bet

Spotting upside in a name is the fun part – but letting a single winner grow into most of your portfolio is how good years get undone in one bad one. Concentration cuts both ways, and selling to spread the risk hands a chunk to the IRS. There is a way to lock in the gains and diversify without the tax hit.